UNSPSC 51401570: Midazolam maleate

This classification denotes a benzodiazepine with the molecular formula C18H13ClFN3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 77520S18SE, chemically known as 8-chloro-6-(o-fluorophenyl)-1-methyl-4h-imidazo(1,5-a)(1,4)benzodiazepine maleate (1:1) but more generally known as midazolam maleate, which bears US NIH Compound Identifier 5384200. European Medicines Agency schedules Midazolam maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14573MIG.

Most nations, for tariff and trade purposes, schedule midazolam maleate under HS 29339100 and SITC 51577. As of Q4 2014, MIDAZOLAM MALEATE remains US FDA's Preferred Term for this commodity. SMILES: CC1NCC2N1-C3CCC(CC3C(=NC2)C4CCCCC4F)CL.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51401570 Midazolam maleate (Commodity) shows minimal recent state and local procurement activity aligned with the code's nominal pharmaceutical scope. The single sourced opportunity—Seminole County, Florida's IFB 60459723LAS—solicits Naloxone and Safe Drug Deactivation Systems, not midazolam, indicating a mismatch between the code assignment and the actual work being procured. Midazolam maleate is a sedative medication used in clinical and emergency settings; the Seminole County bid targets opioid-reversal and drug-disposal products, which fall outside midazolam's therapeutic use and supply chain. State and local health departments, county health systems, emergency medical services, and public safety agencies typically source midazolam through pharmaceutical distributors or group purchasing agreements rather than competitive IFBs, but the available record shows no such activity under this code in the recent opportunities block.

Geographic activity is too limited to characterize with confidence. Seminole County's solicitation is the sole entry in the recent-opportunities dataset, and it does not represent genuine midazolam procurement. The due date on that record (July 26, 2023) is substantially prior to the current date (October 20, 2026), further reducing its relevance as a signal of active market conditions. Buyers pursuing midazolam supplies should monitor state health department, county emergency services, and hospital system RFPs and IFBs directly rather than rely on this code as a reliable procurement signal; the code's current tagging appears to be administrative misalignment rather than evidence of a functioning procurement pathway.